Genprex, Inc. (GNPX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Austin, TX, 미국. 현재 CEO는 Ryan Confer.
GNPX 을(를) 보유 IPO 날짜 2018-03-29, 15 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $2.09M.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
